2025

Future meetings and webinars 2025

Global update: 90-day review ended early and cancelled 10,000 grants, millions of people will suffer

Responses to the UK government slashing international aid by 40%

Deleted words from official documents: LGBTQ, diversity, inclusion, transgender

Country update from Nigeria: current impact on HIV services

Semaglutide reduces alcohol and cigarette use in a randomised phase 2 study

News and resources linked to changes in US policy on international aid

Featured Impact of US elections and executive orders on global health: waiver covers PEPFAR with restrictions

IAS public letter: Why HIV could be poised for a monumental comeback

Lenacapavir for PrEP submitted to EMA for EU and global use

New mpox vaccination sites open in the UK

Africa CDC special briefing on mpox and the impact of conflict

EU license for injectable cabotegravir/rilpivirine injections expanded to include adolescents >12 years old

US issues temporary waiver to re-enable PEPFAR

IAS statement: PEPFAR freeze threatens millions of lives

Trump bans travel for US government scientists, presentations restricted, documents disappearing

Almost 1 in 5 people in Switzerland disconnected from HIV care over 10 years: only half reconnected and with advanced infection

BHIVA pregnancy guidelines online for comment: deadline 25 January

Detailed results from PALM007 study: no clinical impact of tecovirimat against mpox clade 1

Tecovirimat news continues: Japan approval includes mpox indication

Looking back through 2024 and forward to 2025…

i-Base appeal: Q&A services and the website in 2025

ART pipeline 2025: exciting dual long-acting combinations and the challenge of generic dolutegravir

Transient impact of lenacapavir against MDR HIV-2 without other active ART

Lenacapavir submitted to the US FDA with an indication for HIV PrEP